Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) Research & Development (2022 - 2025)

Historic Research & Development for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $38.4 million.

  • Entrada Therapeutics' Research & Development rose 2272.77% to $38.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.7 million, marking a year-over-year increase of 1791.07%. This contributed to the annual value of $125.3 million for FY2024, which is 2545.15% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Research & Development is $38.4 million, which was up 2272.77% from $37.9 million recorded in Q2 2025.
  • Entrada Therapeutics' 5-year Research & Development high stood at $38.4 million for Q3 2025, and its period low was $15.7 million during Q4 2022.
  • Its 4-year average for Research & Development is $26.7 million, with a median of $28.3 million in 2023.
  • Per our database at Business Quant, Entrada Therapeutics' Research & Development soared by 8036.98% in 2023 and then surged by 1211.55% in 2025.
  • Entrada Therapeutics' Research & Development (Quarter) stood at $15.7 million in 2022, then soared by 80.37% to $28.3 million in 2023, then grew by 18.08% to $33.4 million in 2024, then increased by 14.83% to $38.4 million in 2025.
  • Its Research & Development stands at $38.4 million for Q3 2025, versus $37.9 million for Q2 2025 and $32.1 million for Q1 2025.